NewsRx

Search our medical news database

Anemia

Prometic Reports Positive Preliminary Phase Ib/ii Data for Pbi-1402 In Chemotherapy-induced Anemia

Published in Blood Weekly, July 26th, 2007

ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces preliminary data from a Phase Ib/II trial with its orally active drug PBI-1402 for the treatment of chemotherapy-induced anemia (CIA). Data highlights include:

Clinical activity confirmed in CIA, a condition associated with a significant rate (e.g., 40-50 percent) of non-response to recombinant erythropoietin (rhEPO);

Two-thirds of patients enrolled in the study increased their hemoglobin levels by an average of 14g/L of blood and one-third of patients maintained their hemoglobin levels;

All patients enrolled with low levels of white blood cells (neutrophils) achieved...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook